40

Nanexa ABFRA Nanexa Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Oct, 2024

Last price

Market cap $B

0.021

Micro

Exchange

XFRA - Deutsche Boerse AG

40M.F Stock Analysis

40

Uncovered

Nanexa AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-23/100

Low score

Market cap $B

0.021

Dividend yield

Shares outstanding

60.696 B

Nanexa AB engages in the development, production, and distribution of medical nanotechnology products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-17. The firm specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.

View Section: Eyestock Rating